The Board of Directors of Dr. Reddy's Laboratories convened on May 12, 2026, approving a series of key governance and leadership decisions under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 2:00 PM IST and concluded at 3:47 PM IST. The decisions span director appointments, auditor changes, and a notable senior management elevation.

Board-Approved Changes at a Glance

The following key decisions were approved at the board meeting, all subject to shareholder approval at the ensuing Annual General Meeting (AGM) where applicable:

Director Appointments and Re-Appointments

Re-appointment of Dr. K P Krishnan as Independent Director

The board approved the re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director for a second term of five consecutive years, from January 7, 2027 to January 6, 2032, not liable to retire by rotation. The re-appointment is based on the recommendation of the Nomination, Governance and Compensation Committee and is subject to shareholder approval at the ensuing AGM. Dr. Krishnan is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Dr. Krishnan is a former IAS officer with 37 years of distinguished service in public policy, economic governance, and regulatory reform across the Government of India, Government of Karnataka, and the World Bank. He has held key national leadership roles, including Secretary, Ministry of Skill Development and Entrepreneurship; Additional/Special Secretary in the Ministries of Finance and Rural Development; and Secretary to the Prime Minister's Economic Advisory Council. He has taught at IIM Bangalore, ISB, and Ashoka University, held the Bok Visiting Professorship at the University of Pennsylvania Law School, and served as IEPF Chair Professor at NCAER, New Delhi. He is currently a Distinguished Fellow at the Isaac Centre for Public Policy, Ashoka University.

Appointment of Mr. Srikanth Velamakanni as Independent Director

The board approved the appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Additional Director, categorized as an Independent Director, for a term of five consecutive years from July 1, 2026 to June 30, 2031, not liable to retire by rotation, subject to shareholder approval at the ensuing AGM. Mr. Velamakanni is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Mr. Velamakanni is the Co-Founder and Group Chief Executive of Fractal, India's first publicly listed pure-play AI company. He also serves as the Chairperson of Nasscom and as a Founder-Trustee of Plaksha University.

Auditor Appointments

Appointment of Statutory Auditors

Based on the recommendation of the Audit Committee, the board approved the appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018) as Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to shareholder approval. Deloitte Haskins & Sells, Mumbai was constituted in 1997 and converted to a Limited Liability Partnership effective November 20, 2013. The firm is registered with the Institute of Chartered Accountants of India and is part of the Deloitte Haskins & Sells & Affiliates network registered with the ICAI.

Re-appointment of Cost Auditors

The board also approved the re-appointment of M/s Sagar & Associates, Cost Accountants (Firm Registration No. 000118) as Cost Auditors for Financial Year 2026-27, based on the recommendation of the Audit Committee. The firm is a peer-reviewed leading firm of Cost & Management Accountants with diversified activities in cost and management accounting, with its registered office at 205, Raghava Ratna Towers, Churag Ali Lane, Abids, Hyderabad – 500001.

Elevation of Sandeep Khandelwal to Senior Management Personnel

The board approved the elevation of Mr. Sandeep Khandelwal, Global Generics India Head, as a Senior Management Personnel and his induction as a member of the Management Council, effective May 12, 2026. Mr. Khandelwal brings 26 years of leadership experience across General Management, Sales, Marketing, and functional roles, with expertise spanning Pharmaceuticals, OTC, FMCG, and Consumer Durables.

Mr. Khandelwal joined Dr. Reddy's Laboratories in 2018 and currently heads the India sub-continent business, a USD 750 million operation spanning India, Nepal, Sri Lanka, Myanmar, Maldives, and Mauritius, leading a 10,000-strong organization across more than 45 divisions and six countries. Under his leadership, the India topline has grown from Rs 2,300 crore to Rs 7,000 crore, EBITDA margins have expanded from 19 percent to 24 percent, and the company's market rank in India has improved from 16th to 9th. Key milestones under his leadership include the Wockhardt and Novartis acquisitions, the establishment of the Nestlé–Dr. Reddy's Nutrition joint venture, and expansion across platforms such as Vaccines, Biologics, Nutrition, OTC, E-commerce, Trade Generics, alternate channels, and rural markets.

Prior to Dr. Reddy's, Mr. Khandelwal held senior leadership roles at Abbott India, including Commercial Director for Women's Health, Gastroenterology, Hepatic and OTC therapies, and Director, Commercial Excellence. Earlier in his career at Marico Limited, he held multiple frontline and enterprise leadership roles, including heading sales for the Rs. 2,100 crore personal care portfolio.

Revised Senior Management Personnel List

Following Mr. Khandelwal's elevation, the revised list of Senior Management Personnel is as follows:

Dr. Reddy's Laboratories has received an Equal-weight rating from Morgan Stanley with a target price of ₹1,259, following a significant regulatory milestone that strengthens the company's complex generics portfolio.

Health Canada Approval Boosts GLP-1 Portfolio

The pharmaceutical company has secured Health Canada approval for its first generic semaglutide, marking a crucial entry into the lucrative GLP-1 market segment. This approval represents a strategic win for Dr. Reddy's Laboratories in the complex generics space, particularly given the growing demand for diabetes and weight management medications.

Revenue Potential and Market Impact

Morgan Stanley estimates that the generic semaglutide approval could generate approximately $200mn in revenue potential by FY27. This substantial revenue opportunity underscores the commercial significance of the company's entry into the GLP-1 market, which has seen tremendous growth driven by increasing prevalence of diabetes and obesity.

The approval strengthens Dr. Reddy's position in the complex generics portfolio, an area that typically offers higher margins and longer market exclusivity compared to traditional generic medications.

Valuation Considerations

Despite the positive regulatory development, Morgan Stanley maintains a balanced outlook on the stock. The brokerage noted that the current valuation of approximately 18x FY28E PE keeps the investment perspective measured.

The Equal-weight rating suggests that while Morgan Stanley acknowledges the positive impact of the semaglutide approval on Dr. Reddy's growth prospects, the current stock valuation appears fairly priced relative to the expected benefits and market conditions.